Literature DB >> 3013297

Activation of ribonuclease L by (2'-5')(A)4-poly(L-lysine) conjugates in intact cells.

B Bayard, C Bisbal, B Lebleu.   

Abstract

Molecular hybrids were synthesized by coupling (2'-5')(A)n oligoadenylates or 2-5A, an intracellular mediator involved in antiviral activity of interferons (IFNs), with poly(L-lysine) used as a membrane carrier. (2'-5')(A)n in its free form was not taken up by cells, probably because of its ionic character. Conjugation with the polypeptide carrier overcame this problem and enabled its pharmacological properties to be developed. The alpha-glycol group of individual (2'-5')(A)n oligomers was oxidized by periodate oxidation and conjugated by an amino reductive reaction to poly(L-lysine), Mr 14 000, in a molar ratio of 5:1. These hybrid molecules left the biologically active 5' end moiety of the (2'-5')(A)n molecule unchanged, and in particular its triphosphate group, and stabilized the molecule by increasing its resistance to phosphodiesterase hydrolysis. A dose-dependent inhibition of virus growth was observed on concomitant incubation of (2'-5')(A)n-poly(L-lysine) conjugates with vesicular stomatitis virus infected L1210 cell cultures. This was a result of the activation of the (2'-5')(A)n-dependent endoribonuclease (RNase L) by intracellularly delivered (2'-5')(A)n as in some IFN-treated virus-infected cells. Indeed, (2'-5')(A)n-poly(L-lysine) conjugates bind RNase L effectively as can be seen from their ability to compete with authentic (2'-5')(A)n in a cell-free radiobinding assay. Moreover, (2'-5')(A)n-poly(L-lysine) conjugates promote transient inhibition of protein synthesis and a characteristic cleavage pattern of ribosomal RNAs in intact cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3013297     DOI: 10.1021/bi00360a038

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Antagonistic effects of cellular poly(C) binding proteins on vesicular stomatitis virus gene expression.

Authors:  Phat X Dinh; Lalit K Beura; Debasis Panda; Anshuman Das; Asit K Pattnaik
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

2.  Characterization of peptide-oligonucleotide heteroconjugates by mass spectrometry.

Authors:  O N Jensen; S Kulkarni; J V Aldrich; D F Barofsky
Journal:  Nucleic Acids Res       Date:  1996-10-01       Impact factor: 16.971

3.  Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site.

Authors:  M Lemaitre; B Bayard; B Lebleu
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

4.  RNase L inhibitor is induced during human immunodeficiency virus type 1 infection and down regulates the 2-5A/RNase L pathway in human T cells.

Authors:  C Martinand; C Montavon; T Salehzada; M Silhol; B Lebleu; C Bisbal
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

5.  Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent.

Authors:  A Zerial; N T Thuong; C Hélène
Journal:  Nucleic Acids Res       Date:  1987-12-10       Impact factor: 16.971

6.  Selective degradation of mRNA: the role of short-lived proteins in differential destabilization of insulin-induced creatine phosphokinase and myosin heavy chain mRNAs during rat skeletal muscle L6 cell differentiation.

Authors:  A Pontecorvi; J R Tata; M Phyillaier; J Robbins
Journal:  EMBO J       Date:  1988-05       Impact factor: 11.598

Review 7.  The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides.

Authors:  Traian V Chirila; Piroska E Rakoczy; Kerryn L Garrett; Xia Lou; Ian J Constable
Journal:  Biomaterials       Date:  2002-01       Impact factor: 12.479

Review 8.  The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation.

Authors:  M R Player; P F Torrence
Journal:  Pharmacol Ther       Date:  1998-05       Impact factor: 12.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.